The Biden administration's new policy,'Test to Treat' initiative not safe

Published On 2022-03-17 12:15 GMT   |   Update On 2022-03-17 12:15 GMT
Advertisement

Joe Biden, The US President in his State of the Union address last week, introduced a new "Test to Treat" initiative that will allow people who test positive for Covid-19 at a pharmacy to receive antiviral pills "on the spot at no cost. In response to the initiative taken by President, the American Medical Association (AMA) expressed concerns that it would bypass the expertise of primary care physicians, who the organization argues are the most suited to prescribe treatments. Leaving prescribing decisions in the hands of people without knowledge of a patient's medical history is dangerous in practice and precedent isn't avdvisable according American Medical Association. It urges that patients who test positive for Covid-19 to contact their physician to discuss treatment options rather than random antiviral prescription.

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News